Search Results - "Zhou, Xiaoou L."

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma by Dimopoulos, Meletios Athanasios, Beksac, Meral, Pour, Ludek, Delimpasi, Sosana, Vorobyev, Vladimir, Quach, Hang, Spicka, Ivan, Radocha, Jakub, Robak, Pawel, Kim, Kihyun, Cavo, Michele, Suzuki, Kazuhito, Morris, Kristin, Pompilus, Farrah, Phillips-Jones, Amy, Zhou, Xiaoou L., Fulci, Giulia, Sule, Neal, Kremer, Brandon E., Opalinska, Joanna, Mateos, María-Victoria, Trudel, Suzanne

“…In patients with relapsed or refractory myeloma, 1-year progression-free survival was 20 percentage points higher with belantamab mafodotin, pomalidomide, and…”
Get full text

DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma by Usmani, Saad Z., Alonso Alonso, Aránzazu, Quach, Hang, Koh, Youngil, Guenther, Andreas, Min, Chang-Ki, Zhou, Xiaoou L., Kaisermann, Morrys, Mis, Lukasz M., Williams, Danaè, Yeakey, Anne, Ferron-Brady, Geraldine, Figueroa, David J., Kremer, Brandon E., Gupta, Ira, Janowski, Wojciech

“…Introduction: The bortezomib, lenalidomide, and dexamethasone (VRd) regimen is an acceptable standard of care (SoC) for both transplant-eligible and…”
Get full text